Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, Børge G. Nordestgaard, Carl E. Orringer

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

Original languageEnglish (US)
Pages (from-to)374-392
Number of pages19
JournalJournal of Clinical Lipidology
Volume13
Issue number3
DOIs
StatePublished - May 1 2019

Keywords

  • Atherosclerotic cardiovascular disease
  • Biomarker
  • Calcific valvular aortic disease
  • Cardiovascular risk
  • Coronary heart disease
  • Cut points
  • Lifestyle
  • Lipoprotein (a)
  • Lp(a)
  • Myocardial infarction
  • Primary prevention
  • Scientific statement
  • Secondary prevention
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association'. Together they form a unique fingerprint.

  • Cite this